127 related articles for article (PubMed ID: 11032025)
21. An estrogen receptor positive MCF-7 clone that is resistant to antiestrogens and estradiol.
Jiang SY; Wolf DM; Yingling JM; Chang C; Jordan VC
Mol Cell Endocrinol; 1992 Dec; 90(1):77-86. PubMed ID: 1301400
[TBL] [Abstract][Full Text] [Related]
22. Cyr61 promotes breast tumorigenesis and cancer progression.
Tsai MS; Bogart DF; CastaƱeda JM; Li P; Lupu R
Oncogene; 2002 Nov; 21(53):8178-85. PubMed ID: 12444554
[TBL] [Abstract][Full Text] [Related]
23. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent.
Chen X; Lowe M; Keyomarsi K
Oncogene; 1999 Oct; 18(41):5691-702. PubMed ID: 10577141
[TBL] [Abstract][Full Text] [Related]
24. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
25. Idoxifene antagonizes estradiol-dependent MCF-7 breast cancer xenograft growth through sustained induction of apoptosis.
Johnston SR; Boeddinghaus IM; Riddler S; Haynes BP; Hardcastle IR; Rowlands M; Grimshaw R; Jarman M; Dowsett M
Cancer Res; 1999 Aug; 59(15):3646-51. PubMed ID: 10446976
[TBL] [Abstract][Full Text] [Related]
26. Combination treatment with fulvestrant and various cytotoxic agents (doxorubicin, paclitaxel, docetaxel, vinorelbine, and 5-fluorouracil) has a synergistic effect in estrogen receptor-positive breast cancer.
Ikeda H; Taira N; Nogami T; Shien K; Okada M; Shien T; Doihara H; Miyoshi S
Cancer Sci; 2011 Nov; 102(11):2038-42. PubMed ID: 21801281
[TBL] [Abstract][Full Text] [Related]
27. Nordihydroguaiaretic acid (NDGA), an inhibitor of the HER2 and IGF-1 receptor tyrosine kinases, blocks the growth of HER2-overexpressing human breast cancer cells.
Zavodovskaya M; Campbell MJ; Maddux BA; Shiry L; Allan G; Hodges L; Kushner P; Kerner JA; Youngren JF; Goldfine ID
J Cell Biochem; 2008 Feb; 103(2):624-35. PubMed ID: 17562544
[TBL] [Abstract][Full Text] [Related]
28. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
29. BCAR1, a human homologue of the adapter protein p130Cas, and antiestrogen resistance in breast cancer cells.
Brinkman A; van der Flier S; Kok EM; Dorssers LC
J Natl Cancer Inst; 2000 Jan; 92(2):112-20. PubMed ID: 10639512
[TBL] [Abstract][Full Text] [Related]
30. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens.
Wilcken NR; Prall OW; Musgrove EA; Sutherland RL
Clin Cancer Res; 1997 Jun; 3(6):849-54. PubMed ID: 9815758
[TBL] [Abstract][Full Text] [Related]
31. The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein.
McGahren-Murray M; Terry NH; Keyomarsi K
Cancer Res; 2006 Oct; 66(19):9744-53. PubMed ID: 17018634
[TBL] [Abstract][Full Text] [Related]
32. An estrogen-responsive element-targeted histone deacetylase enzyme has an antiestrogen activity that differs from that of hydroxytamoxifen.
Demirpence E; Semlali A; Oliva J; Balaguer P; Badia E; Duchesne MJ; Nicolas JC; Pons M
Cancer Res; 2002 Nov; 62(22):6519-28. PubMed ID: 12438246
[TBL] [Abstract][Full Text] [Related]
33. Tamoxifen-bound estrogen receptor (ER) strongly interacts with the nuclear matrix protein HET/SAF-B, a novel inhibitor of ER-mediated transactivation.
Oesterreich S; Zhang Q; Hopp T; Fuqua SA; Michaelis M; Zhao HH; Davie JR; Osborne CK; Lee AV
Mol Endocrinol; 2000 Mar; 14(3):369-81. PubMed ID: 10707955
[TBL] [Abstract][Full Text] [Related]
34. Ectopic expression of cyclin E in estrogen responsive cells abrogates antiestrogen mediated growth arrest.
Dhillon NK; Mudryj M
Oncogene; 2002 Jul; 21(30):4626-34. PubMed ID: 12096339
[TBL] [Abstract][Full Text] [Related]
35. Down-regulation of p21WAF1/CIP1 or p27Kip1 abrogates antiestrogen-mediated cell cycle arrest in human breast cancer cells.
Cariou S; Donovan JC; Flanagan WM; Milic A; Bhattacharya N; Slingerland JM
Proc Natl Acad Sci U S A; 2000 Aug; 97(16):9042-6. PubMed ID: 10908655
[TBL] [Abstract][Full Text] [Related]
36. Allosteric silencing of activating function 1 in the 4-hydroxytamoxifen estrogen receptor complex is induced by substituting glycine for aspartate at amino acid 351.
MacGregor Schafer J; Liu H; Bentrem DJ; Zapf JW; Jordan VC
Cancer Res; 2000 Sep; 60(18):5097-105. PubMed ID: 11016635
[TBL] [Abstract][Full Text] [Related]
37. Expression and regulation of Cyr61 in human breast cancer cell lines.
Tsai MS; Bogart DF; Li P; Mehmi I; Lupu R
Oncogene; 2002 Jan; 21(6):964-73. PubMed ID: 11840342
[TBL] [Abstract][Full Text] [Related]
38. Estrogen-stimulation of postconfluent cell accumulation and foci formation of human MCF-7 breast cancer cells.
Gierthy JF; Lincoln DW; Roth KE; Bowser SS; Bennett JA; Bradley L; Dickerman HW
J Cell Biochem; 1991 Feb; 45(2):177-87. PubMed ID: 2055945
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms of growth arrest by c-myc antisense oligonucleotides in MCF-7 breast cancer cells: implications for the antiproliferative effects of antiestrogens.
Carroll JS; Swarbrick A; Musgrove EA; Sutherland RL
Cancer Res; 2002 Jun; 62(11):3126-31. PubMed ID: 12036924
[TBL] [Abstract][Full Text] [Related]
40. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
Long BJ; Jelovac D; Thiantanawat A; Brodie AM
Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]